E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with platinum-resistant or platinum-refractory high-grade serious ovarian, primary peritoneal, or fallopian tube cancer who have failed standard of care treatment. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with Ovarian Cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10066697 |
E.1.2 | Term | Ovarian cancer recurrent |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10033128 |
E.1.2 | Term | Ovarian cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057529 |
E.1.2 | Term | Ovarian cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10016180 |
E.1.2 | Term | Fallopian tube cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10016182 |
E.1.2 | Term | Fallopian tube cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061269 |
E.1.2 | Term | Malignant peritoneal neoplasm |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To estimate the overall response rate for each cohort (Cohort 1: Platinum-resistant, BRCA negative, and received ≥3 lines of prior therapy, Cohort 2: Platinum-resistant, BRCA negative, and received <3 lines of prior therapy, Cohort 3: Platinum-resistant, BRCA positive, there is no restrictions on number of lines
of prior therapy, but patients must have received prior PARP inhibitor, Cohort 4: Platinum-refractory, BRCA positive or negative, no restrictions on number of
lines of prior therapy) |
|
E.2.2 | Secondary objectives of the trial |
1. To characterize the safety and toxicity
profile of prexasertib, 2. To characterize the PK of prexasertib, 3. To estimate secondary efficacy
measures including DCR (disease control rate), DoR (duration of response), CA-125 response, PFS (progressioin free survival), OS (overall survival) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Women who have histologically or cytologically verified high-grade serous ovarian,
primary peritoneal or fallopian tube cancer.
- Cohorts 1 to 3: Have platinum-resistant disease, which is defined as disease
progression within 6 months of last dose of platinum-based chemotherapy.
- Cohort 4: Have primary platinum-refractory disease defined as disease progression
during or within 4 weeks after the last dose of initial line of platinum-based
chemotherapy.
- Cohort 1: Are BRCA negative and have received 3 or more prior lines of therapy for
high-grade serous ovarian, primary peritoneal, or fallopian tube cancer (including
immunotherapy, targeted therapies, or chemotherapy (systemic or intraperitoneal).
- Cohort 2: Are BRCA negative have received less than 3 prior lines of therapy for
high-grade serous ovarian, primary peritoneal, or fallopian tube cancer (including
immunotherapy, targeted therapies, or chemotherapy (systemic or intraperitoneal).
- Cohort 3: Are BRCA positive and have previously received a PARP inhibitor at any
time following diagnosis.
- Cohort 4: Are BRCA positive or negative; no restriction on number of lines of prior
therapy.
- Have a performance status (PS) of 0 or 1 on the Eastern Cooperative Oncology Group
(ECOG) scale
- Have adequate organ function,
- Must be able and willing to undergo mandatory tumor biopsy which will be collected following determination of eligibility and before treatment (≤28 days before C1D1). Note that the biopsy may be collected prior to the predose Cycle 1 Day 1 pregnancy test and labs. |
|
E.4 | Principal exclusion criteria |
- Cohorts 1-3: Have previously received all of the following agents at any time in the
platinum-resistant setting: gemcitabine, pegylated liposomal doxorubicin, and
paclitaxel. It is acceptable to have received 1 or 2 of these agents for platinumresistant
disease.
- Have known central nervous system (CNS) malignancy or metastasis.
- Have a known serious medical condition (e.g., active infection, increased risk of bleeding events) that, in the opinion of the investigator, would compromise the patient’s ability to adhere to the protocol or tolerate the study treatment.
- Have known factors that may increase the risk of infection while on study drug treatment. These may include, but are not limited to, an indwelling peritoneal catheter or open wounds. Catheters for vascular access are permitted.
- Have at least one of the following:
history of abdominal fistula or gastrointestinal (GI) perforation
intra-abdominal abscess within last 3 months prior to the first dose of study drug
a radiographically confirmed bowel obstruction (including sub-occlusive disease)
within 3 months prior to the first dose of study drug.
- Have a symptomatic human immunodeficiency virus (HIV) infection or symptomatic
activated/reactivated hepatitis A, B, or C (screening is not required).
- Have a serious cardiac condition, such as:
symptomatic congestive heart failure or any uncontrolled cardiac disease
New York Heart Association Class III/IV heart disease
unstable angina pectoris
symptomatic or poorly controlled cardiac arrhythmia
myocardial infarction within the last 3 months
have a QT interval using Fridericia’s correction (QTcF) of >480 msec on more
than one electrocardiogram (ECG) obtained during the baseline (screening) period
family history of long-QT syndrome.
- Have a history of prior radiotherapy to the whole pelvis.
- Have chronic daily treatment with corticosteroids (dose >10 mg/day methylprednisolone
equivalent), excluding inhaled and topical steroids. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall response rate: proportion of all enrolled patients who achieve a best overall response of PR+CR as determined per RECIST version 1.1. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
ORR will be performed when all enrolled patients have completed ≥2 months of follow-up and/or investigator-assessed best response assessments have been completed for all patients. |
|
E.5.2 | Secondary end point(s) |
safety & toxicity: The safety endpoints evaluated will include but are not limited to the following: AEs, SAEs, clinical laboratory tests, ECGs vital signs, and physical examinations
PK: Prexasertib concentrations in plasma
secondary efficacy measures including DCR, DoR, CA-125 response, PFS, OS: DCR: proportion of patients who achieve a best overall
response of CR, PR and SD (for at least 4 months) as
determined per RECIST version 1.1.
DoR: time from the date measurement criteria for CR or PR
(whichever is first recorded) are first met until the first date of
documented PD, per RECIST 1.1 criteria, or the date of death
from any cause in the absence of documented PD.
CA-125 response: at least a 50% reduction in CA-125 levels from a
pretreatment sample that is at least twice the upper limit of the
reference range and obtained within 2 weeks before starting the
treatment, with confirmation after 4 weeks according to GCIG
criteria.
PFS: time from enrollment until the first radiographic
documentation (as assessed by the investigator) of
progression or death from any cause in the absence of
documented PD
OS: time from enrollment until death from any cause |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
All secondary endpoints will be evaluated at the time of the primary endpoint analysis |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 22 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Brazil |
Israel |
Korea, Republic of |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |